-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 21, Hengrui Medicine issued an announcement to reach a cooperation with CStone Pharmaceuticals to introduce anti-CTLA-4 monoclonal antibody CS1002
This is the fourth BD move made public by Hengrui Medicine since the second half of this year
Start BD acceleration, one external cooperation every month
Start BD acceleration, one external cooperation every monthSince the beginning of this year, Hengrui Pharmaceutical's foreign cooperation projects have increased significantly
In late August, Hengrui reached a cooperation with Dalian Wanchun, a subsidiary of Wanchun Pharmaceutical, to invest 100 million yuan in equity in Dalian Wanchun, and paid a total of not more than 1.
At the end of the same month, Hengrui signed a contract with Beijing Tianguangshi Biotechnology Co.
In mid-September, Hengrui and Qiyu Biotech reached a strategic cooperation agreement to carry out clinical trials of Hengrui Medicine Apatinib combined with Qiyu BioQ-1802 (claudin 18.
In addition to this cooperation with CStone Pharmaceuticals, in just 4 months, Hengrui has reached cooperation with 4 counterparts, involving a total amount of nearly 3 billion yuan
“In fact, Hengrui has been closely monitoring the progress of external innovation and actively introducing high-quality products.
Cooperation is more open, innovation and internationalization are not slack
Cooperation is more open, innovation and internationalization are not slackHengrui's recent open attitude is not only reflected in the frequent BD actions, but also in the exchanges and interactions with external parties including investors
On October 15, Hengrui Pharmaceuticals held its first R&D day since its listing in Shanghai.
On this R&D day, Hengrui executives communicated with investors in a very candid manner
From the recent frequent cooperation projects, Hengrui's words are true
In the first three quarters of this year, Hengrui Pharmaceutical's accumulated R&D investment has reached 4.
In addition to the "walking on two legs" in product layout, Hengrui also "consolidates both internally and externally" in market development-consolidating the domestic market and opening up the international market
Regardless of whether it is self-research + BD, or domestic + international, Hengrui's "walking on two legs" strategy seems to be getting better
Actively embrace changes and accumulate momentum for steady development
Actively embrace changes and accumulate momentum for steady developmentIn the commercial field, integrating resources to achieve win-win cooperation is a rational choice
A little in-depth study reveals that Hengrui's recent external cooperations are basically typical projects that "make up for shortcomings" and "strong advantages"
.
The anti-CTLA-4 monoclonal antibody CS1002 introduced from CStone Pharmaceuticals is a product that Hengrui has not deployed itself.
It can form an important supplement to the existing solid tumor product pipeline and also has greater potential for combination medication; the introduction of Tianguangshi Biotechnology The third-generation anti-CD20 monoclonal antibody MIL62 can be used in combination with Hengrui's various hematoma and kidney disease products to complement each other
.
The prenabulin imported from Dalian Wanchun is a non-G-CSF drug, and it can be used in combination with Hengrui's existing long-acting G-CSF innovative drug thiopefilgrastim (trade name Aido), which can significantly reduce The incidence of severe CIN, the combination of the advantages of the two will produce greater clinical value; the cooperation with Qiyu Bio will directly focus on its own product apatinib mesylate (trade name Aitan) and the other party's Q- The clinical research of 1802 (claudin 18.
2/PD-L1 double antibody) in the treatment of advanced gastric cancer can consolidate Hengrui's dominant position in the field of gastric cancer
.
Go alone fast, and go far
.
Achieving the effect of 1+1>2 through cooperation is an excellent solution for all parties
.
With the rapid development and rapid changes of the pharmaceutical innovation industry, Hengrui, who has always been good at grasping trends and insights into the wind, has made his own choices with actions
.
Throughout the history of Hengrui's development, we have made the right choice at almost every important juncture, and finally achieved the status of "the first brother of innovative medicine" and "the big white horse of A-share medicine"
.
In the face of the new situation, Hengrui strengthens the strategy of "walking on two legs", actively embraces and adapts to changes, or can further accumulate momentum for steady development
.